SOUTH
SAN FRANCISCO, Calif., Aug. 29,
2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.
(Nasdaq: RIGL), a commercial stage biotechnology company focused on
hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial
officer, will participate in the following investor conferences in
September:
- 2024 Wells Fargo Healthcare Conference, Boston, MA
Mr. Schorno will
participate in one-on-one meetings on Thursday, September 5th.
- H.C. Wainwright 26th Annual Global Investment
Conference, New York,
NY
Mr. Schorno will participate in one-on-one
meetings and present a company overview on Tuesday, September 10th at 11:30
a.m. ET.
To access the live webcast or archived recording of the H.C.
Wainwright Conference presentation, visit the Investor Relations
section of the company's website at www.rigel.com. Please connect
to Rigel's website prior to the start of the live webcast to allow
for any software downloads.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)
is a biotechnology company dedicated to discovering, developing and
providing novel therapies that significantly improve the lives of
patients with hematologic disorders and cancer. Founded in 1996,
Rigel is based in South San Francisco,
California. For more information on Rigel, the Company's
marketed products and pipeline of potential products,
visit www.rigel.com.
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-to-participate-in-upcoming-september-investor-conferences-302233721.html
SOURCE Rigel Pharmaceuticals, Inc.
